Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)

Verified September 2016 by National Institutes of Health Clinical Center (CC)

Sponsor:

Information provided by (Responsible Party):

National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

ClinicalTrials.gov Identifier:

NCT01092182

First received: March 23, 2010

Last updated: September 27, 2016

Last verified: September 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2020
Estimated Primary Completion Date:	December 2018 (Final data collection date for primary outcome measure)